Elicio Therapeutics announced the appointment of Robert Connelly as CEO. Elicio is developing precision vaccines, immuno-stimulators, and cellular therapies based on the work of Darrell Irvine, professor of Biological Engineering and Materials Sciences and Howard Hughes Investigator at the Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology.
Over the course of his first six months as NCI director, Anthony Letai has contended with federal budget turbulence, a record-setting government shutdown, and concerns about the flow of over research dollars.
